Piperazines

"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

No definition found.

Descriptor ID	D010879
MeSH Number(s)	D03.383.606
Concept/Terms	Piperazines Piperazines

Below are MeSH descriptors whose meaning is more general than "Piperazines".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperazines [D03.383.606]

Below are MeSH descriptors whose meaning is related to "Piperazines".

Below are MeSH descriptors whose meaning is more specific than "Piperazines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.

Bar chart showing 34 publications over 18 distinct years, with a maximum of 4 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	1	1
1994	1	0	1
2002	1	0	1
2003	1	0	1
2005	2	1	3
2006	2	1	3
2007	1	0	1
2008	0	1	1
2009	2	1	3
2010	1	1	2
2012	1	0	1
2013	0	1	1
2014	2	0	2
2016	2	0	2
2017	1	0	1
2018	2	1	3
2019	2	1	3
2020	2	2	4

Below are the most recent publications written about "Piperazines" by people in Profiles.

Shikdar S, Hall S, Taylor B, de Los Angeles J, Tahirkheli M, Zhao D, Razaq W. Evaluating the Response of Palbociclib on Progression-Free Survival in Hormone Receptor-Positive Metastatic Breast Cancer. Oncology. 2022; 100(6):337-343.

View in: PubMed
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.

View in: PubMed
Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.

View in: PubMed
Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.

View in: PubMed
Tripathi A, Balakrishna P, Agarwal N. PARP inhibitors in castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100199.

View in: PubMed
Ahmad A, Haas De Mello A, Szczesny B, Törö G, Marcatti M, Druzhyna N, Liaudet L, Tarantini S, Salomao R, Garcia Soriano F, Szabo C. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis. Shock. 2020 05; 53(5):653-665.

View in: PubMed
Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070.

View in: PubMed
Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449.

View in: PubMed
Lee KA, Shepherd ST, Johnston SR. Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Oct; 15(29):3309-3326.

View in: PubMed
Washington C, Gunderson CC, Moore KN. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Curr Opin Obstet Gynecol. 2019 02; 31(1):4-11.

View in: PubMed

People

Explore

Similar Concepts

Top Journals